A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosine to Assess Safety and Ability to Elevate Urate in Early Parkinson's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2014

At a glance

  • Drugs Inosine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SURE-PD
  • Most Recent Events

    • 03 May 2014 Results reporting effects of treatment on total antioxidant capacity presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 03 Apr 2012 Planned end date 1 May 2012 added as reported by Oregon Health and Science University Institutional Review Board.
    • 03 Apr 2012 New source identified and integrated (Oregon Health and Science University Institutional Review Board).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top